AUTHORS
Yangmin Zhu, Xiaoting Zhang2, Zhi Liu3, Jing Huang4, Zhao Yin5, Qing Zhang6, Guo-Pan Yu, MD7
AFFILIATIONS
1 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
2 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
3 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
4 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
5 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
6 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
7 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, China
ABSTRACT
Background and Methods: Chimeric antigen receptor (CAR)-T cell therapy is recommended as a salvage treatment for patients with relapsed or refractory multiple myeloma (RRMM). However, there are increasing reports of antigen escape and resistance in single-target CAR-T cell therapy, and dual-target therapy is a promising strategy. Our preclinical study showed great specific immunological cytotoxicity of GPRC5D/CD19 dual-target CAR-T cells with good toleration (Patent no. ZL202310704143.X). Here, we conducted a prospective, single-center, phase I/II trial (NCT06298266) to evaluate the safety and preliminary efficacy of GPRC5D/CD19 dual-target CAR-T cell therapy in patients with RRMM. Patients were infused with dose-escalated GPRC5D/CD19 CAR-T cells at 1, 2, and 3×10⁶/kg for each of three cases in the phase I study, and the recommended phase II dose (RP2D) was determined. Fludarabine and cyclophosphamide (FC) were used for lymphodepletion. The primary endpoint was safety (CRS, ICANS, off-tumor toxicity, and hematologic toxicities), and the secondary endpoints included efficacy (ORR, CR, VGPR, PR, MRD negativity, and PFS), and CAR-T cell expansion/persistence. Responses were assessed according to the IMWG criteria, with the best response categorized as CR, VGPR, or PR.
Results:
Baseline characteristics: Nineteen patients were enrolled in the trial, and an additional eight patients received compassionate use with a rigorous ethical review and informed consent, who had rapidly progressive disease precluding adequate washout periods, active infections, or compromised organ function, bringing the total number of treated patients to 27. All 27 patients were included, of whom 24 were evaluable for efficacy. The median age was 60 years (range, 38–75 years), high/ultra-high-risk cytogenetics were present in 70.8% (17/24), median prior lines of therapy were 3 (range, 1–6), and 20.8% (5/24) had failed prior BCMA-CAR-T therapy. Extramedullary disease (EMD) was observed in 41.7% (10/24) of patients, and plasma cell leukemia (PCL) was observed in 20.8% (5/24) of patients. Compassionate-use patients had a higher baseline tumor burden, more EMD (62.5% vs. 31.6%), and high-risk cytogenetics (87.5% vs. 63.2%) than trial patients did.
Safety: All 27 patients experienced CRS (grade 1: 74.1% [n=20], grade 2: 25.9% [n=7]), with no grade ≥3 CRS or ICANS. The most common grade ≥3 hematologic adverse events were neutropenia (100%), lymphopenia (100%), thrombocytopenia (96.3%), and anemia (88.9%). B cell aplasia occurred in 100% of the patients. Non-hematologic toxicities included hypoproteinemia (66.7%), hypokalemia (55.6%), infections (40.7%), rash (11.1%), and dysgeusia (7.4%); all cases of rash and dysgeusia were grade 1–2.
Efficacy: Among 24 evaluable patients, the ORR was 91.7%, with a CR rate of 62.5%, VGPR rate of 20.8%, and PR rate of 8.3%. The MRD-negative rate was 87.5%. Among the five patients who failed prior BCMA-CAR-T therapy, three (60.0%) achieved CR, and two (40.0%) achieved VGPR. Among the 10 patients with EMD, 7 (70.0%) achieved CR, 2 (20.0%) achieved VGPR, and 1 achieved PR. In the trial cohort (n=19), 17 were evaluable, with an ORR of 94.1%, CR rate of 70.6%, VGPR rate of 17.6%, and PR rate of 5.9%. In the compassionate-use cohort (n=8), 7 were evaluable, with an ORR of 85.7%, CR rate of 42.9%, VGPR rate of 28.6%, and PR rate of 14.3%. With a median follow-up of 7.6 (0.7–20.2) months, the median PFS was not reached, and the 9-month PFS rate was 82.5%.
CAR-T kinetics: The median time to peak CAR copy number was 10 days (IQR 7–14), with a median peak of 6800 copies/μg DNA. CAR-T cells remained detectable in 65% and 40% of patients at 3 and 6 months, respectively.
Conclusion: This is the first worldwide prospective clinical study to evaluate GPRC5D/CD19 dual-targeted CAR-T therapy in RRMM. It demonstrated a favorable safety profile with manageable CRS, no neurotoxicity, mild off-target effects, and potent antitumor activity, even in highly refractory populations, including those with prior BCMA-CAR-T failure and extramedullary disease. The dual-targeting strategy represents a promising novel therapeutic option for RRMM and warrants further validation in larger patient cohorts.
DISCLOSURES
Yangmin Zhu: No relevant conflicts of interest to declare.